Hematologic Malignancy
Aggressive B-Cell Non-Hodgkin Lymphoma
CI-CAN-00001751Explore in graph →
Hematologic115 active trials4 evidence items
- NCIt
- C178541
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001751Explore in graph →
Clinical trials
400 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (72)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04512716 | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | recruiting | Early Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07168291 | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma | not yet recruiting | Early Phase 1 | 3 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER |
| 1 |
| Sep 17, 2025 |
| clinicaltrials |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | terminated | Early Phase 1 | 2 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT01184885 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | completed | Early Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT01239875 | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | completed | Early Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01719250 | Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Early Phase 1 | 7 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01959477 | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant | completed | Early Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00017381 | Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Feb 17, 2026source: clinicaltrials